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Abstract: We investigated the effects of two novel copper-based inorganic formulations 
for their activity against 60 isolates of Helicobacter pylori (Hp). The two copper-based 
formulations were tested against three NCTC Helicobacter pylori isolates and 57 clinical 
strains isolated from the UK and Italy in time-kill assays. Both copper-based formulations 
were bio-cidal against all Helicobacter pylori strains tested reducing the viable count by  
4–5 log within 2 h. These two copper-based anti-microbial agents deserve further study in 
relation to the treatment of H. pylori-related gastric disease. 
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1. Introduction  
Helicobacter pylori is a gram negative, microaerophilic bacterium found principally in the  
stomach [1]. Infection with this organism is one of the most widespread human infections that affects 
up to 50% of the world’s population. Epidemiological studies have clearly demonstrated a major 
aetiological role for Helicobacter pylori in peptic ulcer disease, gastric MALT [mucosal associated 
lymphoid tissues] lymphoma, and distal gastric cancer [2–5]. Clarithromycin or metronidazole 
combined with amoxicillin and a proton pump inhibitor is the most frequently used regimen for  
first-line Helicobacter pylori therapy (standard triple therapy) in clinical practice in Europe as well as 
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US [6]. This regimen is also advocated in the European Helicobacter Study Group (EHSG) Maastricht 
2006 Guidelines. However, there are a number of problems with this approach. Currently, standard 
triple therapy fails to eradicate Helicobacter pylori infection in more than a third of patients [7]. 
Increasing primary resistance to clarithromycin or metronidazole, reported by different studies [8–10], 
is widely claimed as the most important factor reducing the efficacy of therapy. The prevalence of 
clarithromycin resistance varies between 6.1% to 14.5% in the USA and may be as high as 24% in 
some European countries, while the prevalence of metronidazole resistance ranges from 25% to 38% 
in Western countries, and up to 77% in some Asian countries. Amoxycillin resistance is rare. In a 
recent study, increasing rates of clarithromycin resistance (8.7%, 23.5% 26.7%, 34.5% were paralleled 
by falling eradication rates (90.6%, 80.2% 76% 74.8%) respectively [11].  
A recently suggested first line treatment is sequential therapy, where the main aim is to overcome 
clarithromycin resistance [12]. Amoxycillin is given for five days followed by the addition of 
clarithromycin and a nitroimidazole for five days with a proton pump inhibitor given for the whole 10 
days. Reported eradication rates are over 93.4% and are thus much better than current triple therapy 
results [13]. However, even this is only a Grade B success: a Grade A success is defined as >95% 
eradication [14–16]. It has also been suggested that sequential therapy should be a second-line therapy 
not a first line therapy. In areas where clarithromycin resistance is low, various modifications of 
sequential therapy have been used but none achieving Grade A eradication.  
The management of Helicobacter pylori infection after a failed course of initial treatment is 
considered more difficult, mainly due to selection of bacterial strains resistant to the antibiotics used in 
the primary eradication attempt. Thus, optimal therapy after first-line treatment failure remains 
controversial due to the lack of large randomized cohort studies and the lack of homogeneity of 
patients studied. In second or third line therapy, only a few antibiotics against Helicobacter pylori 
infection are suitable, such as bismuth compounds, levofloxacin, rifabutin or furazolidone, which are 
used in triple or quadruple regimes [6].  
In summary, the treatment of Helicobacter associated disease is beset by the following problems: 
(1) Increasing antibiotic resistance; (2) Decreasing eradication rates from >90% to ~70%; (3) The need 
to take lots of tablets and therefore compliance problems leading to antibiotic resistance and failure of 
eradication; (4) The association of proton pump inhibitor use with Clostridium difficile colitis [17]. For 
these reason potential alternative treatments have been investigated such as inhibition of binding [18], 
photodynamic therapy [19], biocidal action of spices [20], anti-malarial drugs [21], essential oils [22] 
and other botanical extracts [23]. In this study, we have investigated the efficacy of novel highly 
reductive copper compounds for their bactericidal activity against Helicobacter pylori.  
2. Results and Discussion  
2.1. Kill Curves of 5 NCTC/Clinical Isolates  
Both CuAL42 and CuPC33 had significant antimicrobial activity against Helicobacter pylori. A kill 
curve of ATCC strain J99 is illustrated in Figure 1. The kill curve of two NCTC isolates that were 
either Type II (cagA negative) or Type I (cagA positive) and 2 clinical isolates that were separately 
metronidazole resistant or clarithromycin resistant is illustrated in Figure 2 (a–d respectively) and 
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demonstrated both compounds had similar activity and killed or reduced the number of bacteria by log 
>6 at 12 ppm, irrespective of virulence marker or antibiotic sensitivity.  
Figure 1. Time-kill curves with CuAL42 and CuPC33 on the antibiotic-sensitive H. pylori 
strain, J99.Star, control; closed square, CuAL42 0.5 mg/L; closed triangle, CuAL42  
1 mg/L; closed upside-down triangle, CuAL42 5 mg/L; closed diamond, CuAL42 12 mg/L; 
open square, CuPC33 0.5 mg/L; open triangle, CuPC33 1 mg/L; open upside-down 
triangle, CuPC33 5 mg/L; open diamond, CuPC33 12 mg/L. The results shown are the 
means of triplicate observations. Error bars representing standard deviations (less than 
10%) are not shown for reasons of clarity. 


















metronidazole-resistant and (d) clarithromycin-resistant H. pylori strains. Star, control; 
closed square, CuAL42 5 mg/L; closed triangle, CuAL42 12 mg/L; open square, CuPC33  
5 mg/L; open triangle, CuPC33 12 mg/L. The results shown are the means of triplicate 
observations. Error bars representing standard deviations (less than 10%) are not shown for 
reasons of clarity. 
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2.2. Activity of CuAL42 and CuPC33 against 57 Clinical Isolates 
The average reduction of viability for the 57 isolates is shown in Figure 3. The reduction in viability 
for both CuPC33 and CuAL42 was significant (p = 0.0001). The number of strains that were killed at 1 
and 2 h is shown in Figure 4 where CuAL42 was slightly more active than CuPC33.  
The resistance rates of the clinical isolates were clarithromycin, (41%) metronidazole (58%) and 
levofloxacin (20%). Antibiotic resistance bore no relationship to the efficacy of the copper compound.  
Figure 3. Mean Activity of CuAL42&CuPC33 against 53 clinical isolates of H. pylori. 
(AL42 = CuAL42; PC33 = CuPC33).  
 
Figure 4. Number of H. pylori isolates killed at one hour (T1) and two hours (T2) by 
CuAL42 and CuPC33 (PC33 = CuPC33; AL42 = CuPC42).  
 
2.3. Discussion 
Previous studies have demonstrated these copper complexes killed Acinetobacter baumanii 
(ACCB) and methicillin resistant Staphylococcus aureus (MRSA) at a concentration of 150 ppm 
within 2 h, compared to equivalent concentrations of copper sulfate and the inorganic binders. At a 
concentration of 20 ppm the copper-based compounds also completely inhibited colony formation of 
ACCB and MRSA, but this required 16 hr of exposure [24]. More recently organo-metallic complexes 
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including copper-fluoroquinolone have shown good antimicrobial activity against a small number of 
Helicobacter pylori strains [25]. In this study, we have analyzed the activity of CuPC33 and CuAL42 
copper complexes against 60 stains of Helicobacter pylori and shown bactericidal activity against all 
isolates at a low concentration (12 ppm) within a period of 2 h. With increasing time, increasing 
numbers were killed. The specific advantage of the CuPC33 and CuAL42-complexes in this study, 
over the antibiotic-metal complexes [25], is the absence of any antibiotic. This suggests a lack of 
generating antibiotic resistant strains and possible not predisposing the patient to Clostridium difficile 
associated disease, although these effects would have to be confirmed by future work.  
Several mechanisms and target sites of action have been proposed for this very broad spectrum of 
biocidal activity of copper. Firstly, copper is a highly redox-active metallo-ion that promotes 
membrane lipid peroxidation, which in turn damages bacterial plasma membrane integrity [26]. 
Secondly, copper binds and disorders helical DNA by engaging this structure at two different binding 
sites, explaining its activity against a wide range of viruses [27]. Thirdly, copper facilitates free 
radical–mediated degradation of proteins, which includes on the one hand oxidation of specific amino 
acid residues, and on the other degradation of sulfydryl moieties [28]. The mechanism by which the 
inorganic binders so effectively enhance copper’s biocidal activity is currently under investigation. 
Preliminary experiments using scanning electron microscopy indicate that exposure of ACCB to 
CuAL42 (150 ppm) for 20 min causes extensive membrane ―blebbing‖ [24].  
Previous work has indicated a lack of cytotoxicity for eukaryotic cells indicating a selective toxicity 
for bacterial cells at the concentrations used [24,29]. Eukaryotic cells have a recognized ability to 
withstand copper toxicity by well characterized, often highly complex mechanisms of intracellular 
protein-dependent coordination, chelation, and transport, and to well characterized extracellular 
binding pathways in multicellular higher organisms [30].  
Finally, the use of copper complex for Helicobacter pylori-associated peptic ulcer disease has one 
further possible advantage: that of enhancing ulcer healing. One of the earliest events in ulcer healing 
is rapid epithelial cell migration leading to reconstitution of the epithelium [31]. This is followed  
by cell proliferation, which restores the mucosal epithelium to its normal thickness. Angiogenesis is 
essential for providing blood flow to the re-establishing epithelium and for the creation of new  
glands [32]. In animal models, it has been shown that the ulcer repair process can be accelerated  
by the administration of epidermal growth factor (EGF) via an effect on both angiogenesis and  
re-epithelialization [33]. Copper is recognized to have angiogenic properties by stimulating VEGF and 
hypoxia-inducible factor-1 alpha [34,35] and it is not unreasonable to suppose that these copper 
complexes may have a similar action, although experimental data is currently lacking.  
3. Experimental  
3.1. Materials 
Bacteria: 3 NCTC cultures—NCTC11637, NCTC 12908, ACTC J99 and 57 clinical isolates, 43 
from Italy and 14 from the UK were used. Copper compounds: The two copper-based formulations—
CuPC33 and CuAL42—were provided by Remedy Research Ltd. These formulations are composed of 
copper sulfate and two inorganic compounds that form the metallo-ion binders. The binders comprise 
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an ammonium salt and an inorganic acid—ammonium phosphate and phosphoric acid in PC33 and 
ammonium sulfate and sulfuric acid in AL42. The concentration of elemental copper in each stock 
solution was 30.43 g/L. 
3.2. Determination of Antibiotic Sensitivity  
Clarithromycin, levofloxacin and metronidazole sensitivity was determined on all isolates using 
European Guidelines [36]. Briefly, testing was performed on Muller Hinton agar containing 10% horse 
blood with an inoculum of 0.5 × 10
9
. Plates were incubated at 37 °C in a micro-aerobic atmosphere 
(CampyGen Oxoid, Basingstoke, UK) for 3 days. Clarithromycin and levofloxacin resistance was 
determined by E test (AB Biodisc Solna Sweden) with resistance recorded as > or equal to 1.0 g/mL 
for both and resistance to metronidazole determined by breakpoint agar streak with growth at 8.0 g/mL 
denoting resistance.  
3.3. Determination of Activity of CuAL42 and CuPC33  
Cag A positive (NCTC11637); CagA negative (NCTC 12908 and ACTC J99) and 57 clinical 
isolates were tested. For 5 of the isolates (3 Type strains and 2 clinical isolates) a time-kill curve was 
performed with an inoculum of 10
7−8
 cfu/mL in sterile water at differing concentrations (0.5, 1.0, 5.0, 
and 12 ppm) of the two copper compounds CuAL42 and CuPC33 against a control containing either 
sterile water, copper sulfate or binders, for 30, 60 and 120 minutes. At each time point, samples were 
withdrawn, decimal diluted into ¼ strength Ringers lactate, plated onto blood agar (Oxoid Ltd.) and 
incubated. Subsequently all the isolates were tested by agar incorporation using Muller Hinton agar 
with 10% horse blood at the same inoculum against 12 ppm for 60 and 120 mins. The plates were 
incubated for 5 days at 37 °C in an atmosphere generated by CampyGen (Oxoid Ltd.).  
3.4. Statistics 
A student’s t-test was performed comparing the mean viable count of the control against the test for 
both agents at T1 and T2.  
4. Conclusions  
Our conclusions are that these reductive copper compounds deserve further studies in relation to the 
mechanism of killing, resistance rate and effects on ulcer healing separate from the bactericidal activity 
reported here.  
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